Antisense-induced exon exclusion in myostatin

Patent metadata

Field	Value
Publication number	US-11015200-B2
Application number	US-201615559257-A
Country	US
Kind code	B2
Filing date	Mar 18, 2016
Priority date	Mar 18, 2015
Publication date	May 25, 2021
Grant date	May 25, 2021

Abstract

The present disclosure relates to antisense oligomers and related compositions and methods for decreasing the expression of functional human myostatin and methods for treating muscular dystrophy and related disorders and more specifically relates to inducing exclusion of myostatin exon 2 and thereby reducing the levels of myostatin protein.

First claim

What is claimed is:

1. An antisense oligomer compound of consisting of a sequence selected from SEQ ID NOS: 2-5, 10-15, and 17-30, wherein X is independently selected from uracil (U) or thymine (T), comprising:
at least one subunit that is a nucleotide analog having (i) a modified internucleoside linkage, (ii) a modified sugar moiety, or (iii) a combination of the foregoing.

2. The antisense oligomer compound of claim 1 , wherein the modified internucleoside linkage is selected from a phosphorothioate internucleoside linkage, a phosphoramidate internucleoside linkage, a phosphorodiamidate internucleoside linkage, or a phosphorodiamidate wherein the phosphorous atom is covalently bonded to a (1,4-piperazin)-1-yl moiety, a substituted (1,4-piperazin)-1-yl moiety, a 4-aminopiperidin-1-yl moiety, or a substituted 4-aminopiperidin-1-yl moiety.

3. The antisense oligomer compound of claim 1 , further comprising an arginine-rich cell-penetrating peptide covalently bonded to the 3′ or the 5′ end of the antisense oligomer compound.

4. The antisense oligomer compound of claim 1 , wherein a nucleobase of each of the subunits is independently adenine, guanine, thymine, uracil, cytosine, inosine, hypoxanthine, 2,6-diaminopurine, 5-methyl cytosine, C5-propynyl-modified pyrimidines, or 10-(9-(aminoethoxy)phenoxazinyl).

5. A compound of formula (I):

or a pharmaceutically acceptable salt thereof, wherein:
each Nu is a nucleobase which taken together form a targeting sequence;
Z is an integer from 15 to 25;
each Y is independently selected from O and —NR 4 , wherein each R 4 is independently selected from H, C 1 -C 6 alkyl, aralkyl, —C(═NH)NH 2 , —C(O)(CH 2 ) n NR 5 C(═NH)NH 2 ,
—C(O)(CH 2 ) 2 NH 5 C(O)(CH 2 )NR 5 C(═NH)NH 2 , and G, wherein R 5 is selected from H and C 1 -C 6 alkyl and n is an integer from 1 to 5;
T is selected from OH and a moiety of the formula:

wherein:
A is selected from —OH, —N(R 7 ) 2 , and R 1 wherein:
each R 7 is independently selected from H and C 1 -C 6 alkyl, and

R 6 is selected from OH, —N(R 9 )CH 2 C(O)NH 2 , and a moiety of the formula:

wherein:
R 9 is selected from H and C 1 -C 6 alkyl; and
R 10 is selected from G, —C(O)—R 11 OH, acyl, trityl, 4-methoxytrityl,
—C(═NH)NH 2 , —C(O)(CH 2 ) m NR 12 C(═NH)NH 2 , and
—C(O)(CH 2 ) 2 NHC(O)(CH 2 ) 5 NR 12 C(═NH)NH 2 , wherein:
m is an integer from 1 to 5,
R 11 is of the formula —(O-alkyl) y — wherein y is an integer from 3 to 10 and each of the y alkyl groups is independently selected from C 2 -C 6 alkyl; and
R 12 is selected from H and C 1 -C 6 alkyl;

each instance of R 1 is independently selected from:
—N(R 13 ) 2 , wherein each R 13 is independently selected from H and C 1 -C 6 alkyl;
a moiety of formula (II):

wherein:
R 15 is selected from H, G, C 1 -C 6 alkyl, —C(═NH)NH 2 ,
—C(O)(CH 2 ) q NR 18 C(═NH)NH 2 , and
—C(O)(CH 2 ) 2 NHC(O)(CH 2 ) 5 NR 18 C(═NH)NH 2 , wherein:
R 18 is selected from H and C 1 -C 6 alkyl; and
q is an integer from 1 to 5; and

each R 17 is independently selected from H and methyl; and

a moiety of formula(III):

wherein:
R 19 is selected from H, C 1 -C 6 alkyl, —C(═NH)NH 2 , —C(O)(CH 2 ) r NR 22 C(═NH)NH 2 ,
—C(O)CH(NH 2 )(CH 2 ) 3 NHC(═NH)NH 2 ,
—C(O)(CH 2 ) 2 NHC(O)(CH 2 ) 5 NR 22 C(═NH)NH 2 , —C(O)CH(NH 2 )(CH 2 ) 4 NH 2 and G,
wherein:
R 22 is selected from H and C 1 -C 6 alkyl; and
r is an integer from 1 to 5,

R 20 is selected from H and C 1 -C 6 alkyl; and

R 2 is selected from H, G, acyl, trityl, 4-methoxytrityl, C 1 -C 6 alkyl, —C(═NH)NH 2 , —C(═NH)NH 2 , —C(O)—R 23 ,
—C(O)(CH 2 ) s NR 24 C(═NH)NH 2 ,
—C(O)(CH 2 ) 2 NHC(O)(CH 2 ) 5 NR 24 C(═NH)NH 2 , —C(O)CH(NH 2 )(CH 2 ) 3 NHC(═NH)NH 2 , and a moiety of the formula:

wherein,
R 23 is of the formula —(O-alkyl) v —OH wherein v is an integer from 3 to 10 and each of the v alkyl groups is independently selected from C 2 -C 6 alkyl; and
R 24 is selected from H and C 1 -C 6 alkyl;
s is an integer from 1 to 5;
L is selected from —C(O)(CH 2 ) 6 C(O)—and —C(O)(CH 2 ) 2 S 2 (CH 2 ) 2 C(O)—; and
each R 25 is of the formula —(CH 2 ) 2 OC(O)N(R 26 ) 2 wherein each R 26 is of the formula —(CH 2 ) 6 NHC(═NH)NH 2 ,

wherein G is a cell penetrating peptide (“CPP”) and linker moiety selected from —C(O)(CH 2 ) 5 NH—CPP, —C(O)(CH 2 ) 2 NH—CPP, —C(O)(CH 2 ) 2 NHC(O)(CH 2 ) 5 NH—CPP, and —C(O)CH 2 NH—CPP, or G is of the formula:

wherein the CPP is attached to the linker moiety by an amide bond at the CPP carboxy terminus, with the proviso that up to one instance of G is present, and
wherein the targeting sequence consists of a sequence selected from SEQ ID NOS: 2-5, 10-15, and 17-30 and wherein X is independently selected from uracil (U) or thymine (T).

6. The compound of claim 5 , wherein each Nu is independently adenine, guanine, thymine, uracil, cytosine, inosine, hypoxanthine, 2,6-diaminopurine, 5-methyl cytosine, C5-propynyl-modified pyrimidines, or 10-(9-(aminoethoxy)phenoxazinyl).

7. The compound of claim 5 , wherein the targeting sequence is selected from SEQ ID NOS: 24 or 29.

8. The compound of claim 5 , wherein Y is O, R 2 is selected from H or G, R 3 is selected from an electron pair or H.

9. The compound of claim 8 , wherein R 2 is G, and wherein the CPP is of a sequence selected from SEQ ID NOS: 32-47.

10. The compound of claim 5 , wherein each R 1 is —N(CH 3 ) 2 .

11. The compound of claim 5 , wherein T is of the formula:

12. The compound of claim 5 , wherein T is of the formula:

wherein A is —N(CH 3 ) 2 , and R 6 is of the formula:

wherein R 10 is G, and
wherein G is —C(O)CH 2 NH—CPP.

13. The compound of claim 12 , wherein the CPP is of a sequence selected from SEQ ID NOS: 32-47.

14. The antisense oligomer compound of claim 1 , wherein the targeting sequence is selected from SEQ ID NOS:17-29.

Assignees

• Sarepta Therapeutics Inc

Inventors

• Schnell Frederick Joseph
• Bestwick Richard Keith

Classifications

• C12N2310/3233

  Morpholino-type ring · CPC title

• C12N15/1136 Primary

  against growth factors, growth regulators, cytokines, lymphokines or hormones · CPC title

• C12N2310/346

  having a combination of backbone and sugar modifications · CPC title

• C12N2310/3513

  Protein; Peptide · CPC title

• A61P21/00

  Drugs for disorders of the muscular or neuromuscular system · CPC title